Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Agomelatine, a melatonergic antidepressant with a rapid onset of action, is one of the most recent drugs in the antidepressant category. Agomelatine’s antidepressant actions are attributed to its sleep-promoting and chronobiotic actions mediated by MT1 and MT2 receptors present in the suprachiasmatic nucleus, as well as to its effects on the blockade of 5-HT2c receptors. Blockade of 5-HT2c receptors causes release of both noradrenaline and dopamine at the fronto-cortical dopaminergic and noradrenergic pathways. The combined actions of agomelatine on MT1/MT2 and 5-HT2c receptors facilitate the resynchronization of altered circadian rhythms and abnormal sleep patterns. Agomelatine appeared to be effective in treating major depression. Moreover, evidence exists that points out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Thus, the aim of this narrative review was to elucidate current evidences on the role of agomelatine in disorders other than major depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 1×
“Several studies have demonstrated the anxiolytic properties of agomelatine in animal models [46].”
BackgroundSelf-citationGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Self-citationMontgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Lewy, A. J., Sack, R. L., Singer, C. M., Whate, D. M., & Hoban, T. M. (1988) · Journal of Biological Rhythms · doi:10.1177/074873048800300203 · Cited by 190
Leproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167 · cited 1×
“The accelerating effect of agomelatine was particularly effective if treatment was started three weeks prior to the induced phase shift [7].”
BackgroundSleep and circadian rhythm dysregulation in schizophrenia
Monti, J. M., BaHammam, A. S., Pandi-Perumal, S. R., Bromundt, V., Spence, D. W., Cardinali, D. P., & Brown, G. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.021 · Cited by 157 · cited 1×
“A decreased nocturnal secretion of melatonin has been observed in patients affected by schizophrenia, with the typical diurnal variation in melatonin altered in at least a subgroup of such patients [67].”
BackgroundThe chronobiology and neurobiology of winter seasonal affective disorder
Levitan, R. D. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.3/rlevitan · Cited by 149
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07493 · Cited by 94
Corruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000679 · Cited by 94
Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature
Di Nicola, M., De Risio, L., Battaglia, C., Camardese, G., Tedeschi, D., Mazza, M., Martinotti, G., Pozzi, G., Niolu, C., Di Giannantonio, M., et al. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.004 · Cited by 87
Self-citationRole of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Self-citationAgomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67 · cited 1×
“[63] conducted a 12-week, placebo-controlled, double-blind, randomized, parallel group (vs.”
MethodFornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67 · cited 1×
“[41] assessed the efficacy and safety of adjunctive agomelatine pharmacotherapy in the treatment of acute major depression in type II bipolar disorder (BD-II).”
BackgroundSelf-citation
Cited by
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Circadian depression: A mood disorder phenotype
Carpenter, J. S., Crouse, J. J., Scott, E. M., Naismith, S. L., Wilson, C., Scott, J., Merikangas, K. R., & Hickie, I. B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.045 · Cited by 114
Treating Circadian Rhythm Disruption in Bipolar Disorder
Gold, A. K., & Kinrys, G. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1001-8 · Cited by 102
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Addiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review
Destoop, M., Morrens, M., Coppens, V., & Dom, G. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00311 · Cited by 85
Metadata
- Authors
- De Berardis, D., Fornaro, M., Serroni, N., Campanella, D., Rapini, G., Olivieri, L., Srinivasan, V., Iasevoli, F., Tomasetti, C., De Bartolomeis, A., Valchera, A., Perna, G., Mazza, M., Di Nicola, M., Martinotti, G., & Di Giannantonio, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-01-05
- Volume
- 16
- Issue
- 1
- Pages
- 1111-1130
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2133305361
- Cited by
- 75
- References
- 14
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.